Glutaminergic vagal afferents may mediate both retching and gastric adaptive relaxation in dogs.
We previously reported that intra-4th-ventricular (i.4th.v.) administration of a non-NMDA receptor antagonist, NBQX, abolished vagally induced retching. This study was undertaken to ascertain whether or not the neuronal response in the solitary tract nucleus (NTS) to vagal stimulation and the vago-vagal gastric reflexes induced by non-emetic stimulation are also abolished by NBQX with a similar latency as in the case of retching. Ketamine and thiopental- or chloralose-anesthetized dogs were decerebrated, and the dorsal surface of the medulla was exposed. This study consisted of two series of experiments. In the first series, extracellular neuronal responses in the NTS to pulse-train vagal stimulation were recorded. Effects of NBQX on the neural response and vagally induced fictive retching were observed. In the second series, effects of glutamate receptor antagonists on gastric corpus responses to esophageal or gastric antral distension were observed. Retching was abolished 5-15 min after an i.4th.v. application of NBQX. and the neuronal responses disappeared within 14 min after application in nine of 10 NTS neurons. On the other hand, corpus contractility was inhibited by esophageal distension, and inhibited and/or enhanced by antral distension. While the inhibitory responses disappeared within 17 min after NBQX, the enhanced response remained even after NBQX and vagotomy, but was abolished by i.v. administration of hexamethonium. These results suggest that adaptive relaxation in the corpus, as well as retching, may be mediated by glutaminergic vagal afferents and non-NMDA receptors in the NTS.
Furukawa
N
N
Department of Physiology, Kawasaki Medical School, Kurashiki, Japan. furukawa@med.kawasaki-m.ac.jp
Hatano
M
M
Fukuda
H
H
D000200:Action Potentials / Q000187:drug effects; D000818:Animals; D002404:Catheterization; D016291:Dizocilpine Maleate / Q000494:pharmacology; D004285:Dogs; D004947:Esophagus / Q000294:innervation / Q000502:physiology; D018691:Excitatory Amino Acid Antagonists / Q000494:pharmacology; D005730:Ganglionic Blockers / Q000494:pharmacology; D018698:Glutamic Acid / Q000502:physiology*; D018738:Hexamethonium / Q000494:pharmacology; D009475:Neurons, Afferent / Q000502:physiology*; D011810:Quinoxalines / Q000494:pharmacology; D012018:Reflex / Q000187:drug effects / Q000502:physiology; D017552:Solitary Nucleus / Q000166:cytology / Q000502:physiology; D013270:Stomach / Q000294:innervation / Q000502:physiology*; D014628:Vagotomy; D014630:Vagus Nerve / Q000166:cytology / Q000502:physiology*; D014839:Vomiting / Q000503:physiopathology*
D018691:Excitatory Amino Acid Antagonists; D005730:Ganglionic Blockers; D011810:Quinoxalines; C062865:2,3-dioxo-6-nitro-7-sulfamoylbenzo(f)quinoxaline; D018738:Hexamethonium; D018698:Glutamic Acid; D016291:Dizocilpine Maleate